- Home
- AURE vs RFL Comparison
AURE vs RFL Comparison
Compare AURE & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | AURE | RFL |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Hong Kong | United States |
| Employees | 4 | N/A |
| Industry | Finance: Consumer Services | Real Estate |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.9M | 92.6M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | AURE | RFL |
|---|---|---|
| Price | $2.30 | $2.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.4K | ★ 206.7K |
| Earning Date | 06-01-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.18 | $1.12 |
| 52 Week High | $3.53 | $2.58 |
Technical Indicators
Market Signals| Indicator | AURE | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 83.12 |
| Support Level | $2.33 | $1.22 |
| Resistance Level | $2.59 | N/A |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 31.71 | 100.00 |
Price Performance
Historical ComparisonAbout AURE Prestige Wealth Inc. Class A Ordinary Shares
Aurelion Inc is a Tether Gold (XAUT) Real World Asset (RWA) company focused on developing a business around tokenized gold. XAUT combines the stability of physical gold with the efficiency of blockchain, providing investors access to a tokenized gold reserve that could serve as a haven to inflation, currency devaluation, and crypto volatility. In parallel to building a business around the development of tokenized gold, Aurelion provides wealth management and asset management services.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.